慢性肾脏病患者口服抗凝药的临床药理学
本文综述了口服抗凝药在CKD和ESKD患者中的临床药理学。华法林和阿哌沙班是FDA批准用于CKD和ESKD患者的抗凝药,其他药物常超说明书使用。尿毒症增加出血风险,每种抗凝药药理特性独特,肾内科医生需掌握以优化管理并处理出血不良事件。
要点
- 华法林和阿哌沙班是FDA批准用于CKD和ESKD患者的口服抗凝药。
- 其他口服抗凝药常超说明书用于CKD和ESKD患者,需注意出血风险。
- 每种口服抗凝药对凝血实验室指标影响独特,需个体化监测。
核心结论
- 华法林和阿哌沙班是FDA批准用于CKD和ESKD患者的唯一口服抗凝药,其他药物常超说明书使用。
- 尿毒症增加出血风险,口服抗凝药可导致出血事件、住院和总体发病率增加。
- 肾内科医生需了解每种抗凝药的独特药理特性以优化管理并处理出血不良事件。
研究设计与样本
- 本文为综述,总结口服抗凝药在CKD和ESKD患者中的临床药理学并识别文献知识空白。
主要发现
- 华法林是唯一FDA批准用于机械心脏瓣膜患者的抗凝药。
- 每种口服抗凝药对凝血实验室指标的影响独特。
- 其他口服抗凝药在CKD和ESKD患者中常超说明书使用。
临床怎么用
- 肾内科医生应掌握每种口服抗凝药的药理特性以优化CKD和ESKD患者的抗凝管理。
- 肾内科医生 increasingly 被要求协助管理口服抗凝药相关出血事件。
局限性
- 本文识别了文献中关于口服抗凝药在CKD和ESKD患者中使用的知识空白。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Oral anticoagulants are commonly used drugs in patients with CKD and patients with ESKD to treat atrial fibrillation to reduce stroke and systemic embolism. Some of these drugs are used to treat or prevent deep venous thrombosis and pulmonary embolism in patients with CKD who undergo knee and hip replacement surgeries. Warfarin is the only anticoagulant that is approved for use by the Food and Drug Administration in individuals with mechanical heart valves. Each oral anticoagulant affects the coagulation profile in the laboratory uniquely. Warfarin and apixaban are the only anticoagulants that are Food and Drug Administration approved for use in patients with CKD and patients with ESKD. However, other oral anticoagulants are commonly used off label in this patient population. Given the acquired risk of bleeding from uremia, these drugs are known to cause increased bleeding events, hospitalization, and overall morbidity. Each anticoagulant has unique pharmacologic properties of which nephrologists need to be aware to optimally manage patients. In addition, nephrologists are increasingly asked to aid in the management of adverse bleeding events related to oral anticoagulant use in patients with CKD and patients with ESKD. This article summarizes the clinical pharmacology of these drugs and identifies knowledge gaps in the literature related to their use.
引用
- Jain N, Reilly RF. Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease. Clin J Am Soc Nephrol. 2018. PMID: 29802125. doi:10.2215/CJN.02170218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。